, a bio/informatics shared resource is still "open for business" - Visit the CDS website


  1. Roux-en-Y gastric bypass surgery improves hepatic glucose metabolism and reduces plasma kisspeptin levels in morbidly obese patients with type 2 diabetes. Flynn CR, Albaugh VL, Tamboli RA, Gregory JM, Bosompem A, Sidani RM, Winnick JJ (2020) Am J Physiol Gastrointest Liver Physiol 318(2): G370-G374
    › Primary publication · 31709832 (PubMed) · PMC7052573 (PubMed Central)
  2. Utilizing Untargeted Ion Mobility-Mass Spectrometry To Profile Changes in the Gut Metabolome Following Biliary Diversion Surgery. Poland JC, Schrimpe-Rutledge AC, Sherrod SD, Flynn CR, McLean JA (2019) Anal Chem 91(22): 14417-14423
    › Primary publication · 31573190 (PubMed) · PMC7076733 (PubMed Central)
  3. Two-week administration of engineered Escherichia coli establishes persistent resistance to diet-induced obesity even without antibiotic pre-treatment. Dosoky NS, Chen Z, Guo Y, McMillan C, Flynn CR, Davies SS (2019) Appl Microbiol Biotechnol 103(16): 6711-6723
    › Primary publication · 31203417 (PubMed) · PMC7066869 (PubMed Central)
  4. Treating Nonalcoholic Fatty Liver Disease From the Outside In? Flynn CR (2019) Cell Mol Gastroenterol Hepatol 7(3): 682-683
    › Primary publication · 30677403 (PubMed) · PMC6477184 (PubMed Central)
  5. Systemic bile acids induce insulin resistance in a TGR5-independent manner. Syring KE, Cyphert TJ, Beck TC, Flynn CR, Mignemi NA, McGuinness OP (2019) Am J Physiol Endocrinol Metab 316(5): E782-E793
    › Primary publication · 30779633 (PubMed) · PMC6732652 (PubMed Central)
  6. Role of Bile Acids and GLP-1 in Mediating the Metabolic Improvements of Bariatric Surgery. Albaugh VL, Banan B, Antoun J, Xiong Y, Guo Y, Ping J, Alikhan M, Clements BA, Abumrad NN, Flynn CR (2019) Gastroenterology 156(4): 1041-1051.e4
    › Primary publication · 30445014 (PubMed) · PMC6409186 (PubMed Central)
  7. Metabolic Effects of Bile Acids: Potential Role in Bariatric Surgery. Flynn CR, Albaugh VL, Abumrad NN (2019) Cell Mol Gastroenterol Hepatol 8(2): 235-246
    › Primary publication · 31075353 (PubMed) · PMC6664228 (PubMed Central)
  8. GLP-1: Molecular mechanisms and outcomes of a complex signaling system. Smith NK, Hackett TA, Galli A, Flynn CR (2019) Neurochem Int : 94-105
    › Primary publication · 31002893 (PubMed) · PMC7081944 (PubMed Central)
  9. Regulation of Insulin Receptor Pathway and Glucose Metabolism by CD36 Signaling. Samovski D, Dhule P, Pietka T, Jacome-Sosa M, Penrose E, Son NH, Flynn CR, Shoghi KI, Hyrc KL, Goldberg IJ, Gamazon ER, Abumrad NA (2018) Diabetes 67(7): 1272-1284
    › Primary publication · 29748289 (PubMed) · PMC6014550 (PubMed Central)
  10. In vitro safety pharmacology evaluation of 2-hydroxybenzylamine acetate. Fuller JC, Pitchford LM, Morrison RD, Daniels JS, Flynn CR, Abumrad NN, Oates JA, Boutaud O, Rathmacher JA (2018) Food Chem Toxicol : 541-548
    › Primary publication · 30253245 (PubMed) · PMC6220894 (PubMed Central)